Suven Life Sciences (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at 8th Clinical Trials on Alzheimer’s Disease (CTAD) conference held during November 5-7, 2015 at Barcelona, Spain. Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges.
The goal of 8th Clinical Trials on Alzheimer’s Disease (CTAD) conference is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. During CTAD- 2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.30 |
| Dr. Reddys Lab | 1237.90 |
| Cipla | 1238.95 |
| Zydus Lifesciences | 941.85 |
| Lupin | 2332.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: